Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
, 58 (1), 237-40

On the Use of Nonparametric Curves in Phase I Trials With Low Toxicity Tolerance

Affiliations
Comment

On the Use of Nonparametric Curves in Phase I Trials With Low Toxicity Tolerance

Ying Kuen Cheung. Biometrics.

Abstract

Gasparini and Eisele (2000, Biometrics 56, 609-615) propose a design for phase I clinical trials during which dose allocation is governed by a Bayesian nonparametric estimate of the dose-response curve. The authors also suggest an elicitation algorithm to establish vague priors. However, in situations where a low percentile is targeted, priors thus obtained can lead to undesirable rigidity given certain trial outcomes that can occur with a nonnegligible probability. Interestingly, improvement can be achieved by prescribing slightly more informative priors. Some guidelines for prior elicitation are established using a connection between this curve-free method and the continual reassessment method.

Comment on

Similar articles

See all similar articles

Cited by 8 PubMed Central articles

See all "Cited by" articles

LinkOut - more resources

Feedback